MAPT and amyloidosis: Elevated plasma GFAP levels have been linked to AD, particularly in individuals with early amyloid pathology but without significant tau deposition, suggesting that GFAP may serve as an early marker of amyloid-related neuroinflammation that could help identify individuals at risk of progressing to clinical stages of dementia.19